Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when AUPH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAurinia Q3 revenue up 14% to $83.7M, raises 2026 guidance to $325–330M
Filed October 30, 2026 · Period ending October 30, 2026 · ~1 min read
Key Changes
-
high
Q3 2026 total revenue rose 14% year-over-year to $83.7 million, driven by LUPKYNIS net product sales of $79.4 million (up 12%) and license/collaboration/royalty revenue of $4.3 million (up 54%).
Exhibit 99.1 view on EDGAR → -
high
Management raised full-year 2026 total revenue guidance to $325–330 million (from $315–325 million) and narrowed net product sales guidance to $310–315 million.
Exhibit 99.1 view on EDGAR → -
high
Q3 net income was flat at $31.7 million; nine-month net income grew 35% to $103.5 million, with diluted EPS of $0.23 for the quarter and $0.76 for the nine months.
Exhibit 99.1 view on EDGAR → -
medium
Cash and investments totaled $486.9 million at September 30, 2026, up from $398.0 million at year-end 2025; the company repurchased 5.0 million shares for $74.9 million during the first nine months.
Exhibit 99.1 view on EDGAR → -
medium
Aurinia initiated PRESERVE, a Phase 4 study of LUPKYNIS in combination with belimumab, obinutuzumab, or anifrolumab in lupus nephritis, with planned enrollment of ~150 patients across ~50 U.S. sites.
Exhibit 99.1 view on EDGAR →
Summary
Aurinia Pharmaceuticals reported third-quarter 2026 results showing continued growth in its LUPKYNIS franchise. Total revenue increased 14% year-over-year to $83.7 million, with net product sales of $79.4 million. Net income was essentially flat at $31.7 million for the quarter, while nine-month net income rose 35% to $103.5 million.
The company ended the quarter with $486.9 million in cash and investments, up from $398.0 million at the start of the year, and repurchased 5.0 million shares for $74.9 million during the first nine months.
Management raised full-year 2026 total revenue guidance to a range of $325 million to $330 million, up from the prior $315 million to $325 million, and narrowed net product sales guidance to $310 million to $315 million. This reflects confidence in continued LUPKYNIS growth. Aurinia also announced the initiation of PRESERVE, a Phase 4 study evaluating LUPKYNIS in combination with three biologic agents in lupus nephritis patients. For retail investors, the key takeaways are the revenue growth, the raised guidance, and the company's strong cash position, which supports both the share repurchase program and investment in clinical development. The Phase 4 study could expand the market for LUPKYNIS if successful, but it is still early-stage.
Section-by-Section Diff
Event · Exhibit 99.1
Aurinia reports Q3 2026 revenue up 14% to $83.7M, net income flat at $31.7M, and raises 2026 revenue guidance.
Added in current filing · view on EDGAR →
For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025.
Total revenue grew 14% year-over-year in Q3 2026 to $83.7 million, driven by LUPKYNIS net product sales of $79.4 million (up 12%) and license/collaboration/royalty revenue of $4.3 million (up 54%). For the nine-month period, total revenue rose 19% to $244.6 million.
Added in current filing · view on EDGAR →
Aurinia has recently initiated PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis.
Aurinia initiated a Phase 4 study (PRESERVE) evaluating LUPKYNIS in combination with three biologic agents in lupus nephritis patients. Planned enrollment is approximately 150 patients across roughly 50 U.S. sites, with a primary endpoint of complete renal response at 6 months.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Nov 2, 2026 · How we verify